Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Irritable bowel syndrome (IBS) is a chronic functional disorder and its development may be linked, directly and indirectly, to intestinal dysbiosis. Here we investigated the interactions between IBS symptoms and the gut microbiome, including the relation to rifaximin (1200 mg daily; 11.2 g per a treatment). We recruited 72 patients, including 31 with IBS-D (diarrhea), 11 with IBS-C (constipation), and 30 with IBS-M (mixed constipation and diarrhea) and 30 healthy controls (HCs). Of them, 68%, 64%, and 53% patients with IBS-D, IBS-C, and IBS-M, respectively, achieved 10-12 week-term improvement after the rifaximin treatment. Stool samples were collected before and after the treatment, and fecal microbiotic profiles were analyzed by deep sequencing of 16S rRNA, while stool metabolic profiles were studied by hydrogen 1-nuclear magnetic resonance ((1)H-NMR) and gas chromatography-mass spectrometry (GC-MS). Of 26 identified phyla, only Bacteroidetes, Firmicutes, Proteobacteria, and Actinobacteria were consistently found in all samples. Bacteroidetes was predominant in fecal samples from HCs and IBS-D and IBS-M subjects, whereas Firmicutes was predominant in samples from IBS-C subjects. Species richness, but not community diversity, differentiated all IBS patients from HCs. Metabolic fingerprinting, using NMR spectra, distinguished HCs from all IBS patients. Thirteen metabolites identified by GC-MS differed HCs and IBS patients. However, neither metagenomics nor metabolomics analyses identified significant differences between patients with and without improvement after treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007) · Behavior Research Methods · doi:10.3758/bf03193146 · Cited by 65,971
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
The functional gastrointestinal disorders and the Rome III process
Drossman, D. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.008 · Cited by 2,416
AGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384
Manichanh, C., Borruel, N., Casellas, F., & Guarner, F. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.152 · Cited by 1,160
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Postinfectious Irritable Bowel Syndrome
Spiller, R., & Garsed, K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.074 · Cited by 1,024
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota
Jeffery, I. B., O'Toole, P. W., Öhman, L., Claesson, M. J., Deane, J., Quigley, E. M. M., & Simrén, M. (2012) · Gut · doi:10.1136/gutjnl-2011-301501 · Cited by 835
Ford, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.202 · Cited by 747
Malinen, E., Rinttila, T., Kajander, K., Matto, J., Kassinen, A., Krogius, L., Saarela, M., Korpela, R., & Palva, A. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40312.x · Cited by 699
Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome
Saulnier, D. M., Riehle, K., Mistretta, T., Diaz, M., Mandal, D., Raza, S., Weidler, E. M., Qin, X., Coarfa, C., Milosavljevic, A., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.072 · Cited by 672 · cited 1×
“Pyrosequencing also showed that the abundances of g-Proteobacteria (particularly, the species Haemophilus parainfluenzae) and of the Firmicutes genera Dorea and Veillonella were increased in pediatric IBS patients.(63) The genus Veillonella was also increased in pediatric IBS-D patients.”
BackgroundDiversity of the human gastrointestinal tract microbiota revisited
Rajilić‐Stojanović, M., Smidt, H., & De Vos, W. M. (2007) · Environmental Microbiology · doi:10.1111/j.1462-2920.2007.01369.x · Cited by 559
Intestinal microbiota, diet and health
Power, S. E., O'Toole, P. W., Stanton, C., Ross, R. P., & Fitzgerald, G. F. (2014) · British Journal Of Nutrition · doi:10.1017/s0007114513002560 · Cited by 476
tana, C., umesaki, Y., imaoka, A., handa, T., kanazawa, M., & fukudo, S. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01427.x · Cited by 474 · cited 2×
“The unbalanced fecal organic acid levels in IBS correlated with the altered profile of intestinal microbiota, especially Lactobacilli and Veillonella.(60) (1)H-NMR spectroscopy represents a powerful technique for investigating gut metabolomic profiling,”
BackgroundBajaj, J. S., Heuman, D. M., Sanyal, A. J., Hylemon, P. B., Sterling, R. K., Stravitz, R. T., Fuchs, M., Ridlon, J. M., Daita, K., Monteith, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060042 · Cited by 430
Carroll, I. M., Ringel‐Kulka, T., Siddle, J. P., & Ringel, Y. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01891.x · Cited by 425 · cited 3×
“or Carroll et al.(55) studies, may stem from differences in 16S rRNA sequencing approach: most methods focus on one or 2 hypervariable regions, while kit we used covers 6 regions.”
BackgroundMethodSharara, A. I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S., & ElHajj, I. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00458.x · Cited by 344
Mättö, J., Maunuksela, L., Kajander, K., Palva, A., Korpela, R., Kassinen, A., & Saarela, M. (2005) · FEMS Immunology & Medical Microbiology · doi:10.1016/j.femsim.2004.08.009 · Cited by 301 · cited 1×
“was increased and the prevalence of Eubacterium was decreased in IBS patients.(15) By contrast, another study showed no significant differences between the microbiota compositions of both duodenal biopsies and fecal samples from IBS patients and HCs, except for an increase of Pseudomonas aeruginosa in IBS.”
ResultMenees, S. B., Maneerattannaporn, M., Kim, H. M., & Chey, W. D. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.355 · Cited by 283
Walker, A. W., Martin, J. C., Scott, P., Parkhill, J., Flint, H. J., & Scott, K. P. (2015) · Microbiome · doi:10.1186/s40168-015-0087-4 · Cited by 273
Xu, D., Gao, J., Gillilland, M., Wu, X., Song, I., Kao, J. Y., & Owyang, C. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.10.026 · Cited by 271 · cited 1×
“In addition to clinical studies, oral rifaximin in rats altered the composition of bacterial communities in the ileum and prevented mucosal inflammation, impairment of intestinal barrier function, and visceral hyperalgesia in response to chronic stress.(37) In accordance to the American College of Gastroenterology rec…”
BackgroundIrritable bowel syndrome: A clinical review
Soares, R. L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.12144 · Cited by 266
A Molecular Analysis of Fecal and Mucosal Bacterial Communities in Irritable Bowel Syndrome
Codling, C., O’Mahony, L., Shanahan, F., Quigley, E. M. M., & Marchesi, J. R. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0934-x · Cited by 243
Intestinal microecology and quality of life in irritable bowel syndrome patients
Si, J.-M. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i12.1802 · Cited by 218
Rigsbee, L., Agans, R., Shankar, V., Kenche, H., Khamis, H. J., Michail, S., & Paliy, O. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.287 · Cited by 207
Carroll, I. M., Chang, Y.-H., Park, J., Sartor, R. B., & Ringel, Y. (2010) · Gut Pathogens · doi:10.1186/1757-4749-2-19 · Cited by 203
Metabolite profiling of fecal water extracts from human colorectal cancer
Monleón, D., Morales, J. M., Barrasa, A., López, J. A., Vázquez, C., & Celda, B. (2009) · NMR in Biomedicine · doi:10.1002/nbm.1345 · Cited by 186 · cited 2×
“with the simplicity of sample preparation and the high throughput being its major benefits.(75) Our fingerprint profiling of the lipophilic metabolites in fecal samples from IBS patients provided a 2-group PLS-DA model distinguishing IBS patients from HCs (Fig.”
BackgroundLyra, A., Rinttilä, T., Nikkilä, J., Krogius-Kurikka, L., Kajander, K., Malinen, E., Mättö, J., Mäkelä, L., & Palva, A. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.5936 · Cited by 160
Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy.
(2014) · PubMed Central · doi:10.3748/wjg.v20.i27.8807 · Cited by 132
Yang, J., Lee, H.-R., Low, K., Chatterjee, S., & Pimentel, M. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-9839-8 · Cited by 129
Intestinal microbiota in pathophysiology and management of irritable bowel syndrome.
(2014) · PubMed Central · doi:10.3748/wjg.v20.i27.8886 · Cited by 106
Schoenfeld, P., Pimentel, M., Chang, L., Lembo, A., Chey, W. D., Yu, J., Paterson, C., Bortey, E., & Forbes, W. P. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12735 · Cited by 106
(2014) · PubMed Central · doi:10.3748/wjg.v20.i27.8859 · Cited by 95
Peralta, S., Cottone, C., Doveri, T., Almasio, P. L., & Craxi, A. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2628 · Cited by 88
The effects of ageing on the colonic bacterial microflora in adults
Enck, P., Zimmermann, K., Rusch, K., Schwiertz, A., Klosterhalfen, S., & Frick, J.-S. (2009) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0028-1109055 · Cited by 68
Irritable bowel syndrome: a concise review of current treatment concepts
Wall, G. C., Bryant, G. A., Bottenberg, M. M., Maki, E. D., & Miesner, A. R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.8796 · Cited by 56
Rezaie, A., Nikfar, S., & Abdollahi, M. (2010) · Archives of Medical Science · doi:10.5114/aoms.2010.13507 · Cited by 40
Cited by
Tryptophan Metabolism: A Link Between the Gut Microbiota and Brain
Gao, K., Mu, C.-L., Farzi, A., & Zhu, W.-Y. (2020) · Advances in Nutrition · doi:10.1093/advances/nmz127 · Cited by 1,029
“Treatment with antibiotics or probiotics improves some symptoms in IBS patients (5, 94), suggesting a potential link between intestinal microbes and IBS.”
BackgroundFord, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M., & Moayyedi, P. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15001 · Cited by 619
“microbiome, show that any changes are limited, and are not sustained.(100-102) Although the limited research regarding rates of”
BackgroundAmerican College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388
Prebiotics and Probiotics in Digestive Health
Quigley, E. M. M. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.09.028 · Cited by 380
A review on human fecal metabolomics: Methods, applications and the human fecal metabolome database
Karu, N., Deng, L., Slae, M., Guo, A. C., Sajed, T., Huynh, H., Wine, E., & Wishart, D. S. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.05.031 · Cited by 261
Metadata
- Authors
- Zeber-Lubecka, N., Kulecka, M., Ambrozkiewicz, F., Paziewska, A., Goryca, K., Karczmarski, J., Rubel, T., Wojtowicz, W., Mlynarz, P., Marczak, L., Tomecki, R., Mikula, M., & Ostrowski, J.
- Venue
- Gut Microbes
- Publisher
- Informa UK Limited
- Published
- 2016-08-15
- Volume
- 7
- Issue
- 5
- Pages
- 397-413
- ISSN
- 1949-0976 (ISSN-L)
- 1949-0984
- OpenAlex
- W2409865253
- Cited by
- 78
- References
- 39
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.